Search results
NAPTT Reagent Kit
Liquid "ready for use", containing synthetic phospholipid blend. This kit is intended for use in the European Pharmacopoeia (EP) method for the detection of activated coagulation factors in therapeutic products. Also, the NAPTT reagent alone can be used in the NAPTT test for detecting contact activation and hypercoagulability (For Research Use Only).
Factor X, CoaChrom®
Assay proposed for the measurement of factor X in research applications.
HEMOCLOT Factor VIIa Reagent
Assay proposed for the measurement of factor VIIa activity citrated plasma or purified medium.
BIOPHEN FVIIa Control Set
BIOPHEN FVIIa Control Set is a set of controls intended for the quality control of activated factor VII (FVIIa) activity measurements, the BIOPHEN FVIIs colorimetric assay with the kit BIOPHEN Factor VIIa (ref. 221312) and the clotting assay with the kit HEMOCLOT Factor VIIa assay (ref. CK092K).
CoaChrom® Prothrombin -> SEE NEW REF. 400001
Assay proposed for the measurement of prothrombin (Factor II) in research applications.
BIOPHEN Antithrombin LRT (anti-(h)-Xa, Liquid Reagent Technology)
Diagnosis of congenital or acquired antithrombin deficiencies.
BIOPHEN Antithrombin LRT (anti-(h)-Xa, Liquid Reagent Technology)
Diagnosis of congenital or acquired antithrombin deficiencies.
Ristocetin
The ristocetin reagent is proposed for platelet aggregation tests, as an aid for the detection of von Willebrand disease, von Willebrand factor (vWF) determination, and identification of Bernard-Soulier syndrome.
Collagen
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome, storage pool disease) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.